FDA Misses Six-Month Deadline for Hemp Cannabinoid Lists, CRS Reports

FDA Deadline Lapse Documented in CRS Report

The Congressional Research Service documented the FDA's failure to meet a February 2026 deadline for publishing hemp cannabinoid lists and container guidance mandated by Congress. The CRS report, released to lawmakers on August 24, marks the first official congressional acknowledgment of the agency's delay. The guidance was required under Section 297D of the Agricultural Marketing Act of 1946, as amended by the 2018 Farm Bill.

FDA was tasked with publishing two critical regulatory documents: a comprehensive list of hemp-derived cannabinoids permitted in consumer products and standardized guidance on product container labeling and safety features. Both were due six months after the Farm Bill's hemp provisions took effect in December 2018, setting a June 2019 initial deadline that was later extended to February 2026 under subsequent appropriations language.

The CRS report doesn't speculate on reasons for the delay. It notes the FDA hasn't issued a formal notice of postponement or requested additional time from Congress.

Industry Impact of Missing Guidance

Hemp manufacturers lack clear federal standards for which cannabinoids are permissible in interstate commerce and how products must be packaged. Trade groups have reported compliance paralysis. Manufacturers can't confidently formulate products for national distribution without risking FDA enforcement action.

The Hemp Industries Association estimates the regulatory uncertainty has frozen approximately $1.2 billion in planned capital investment across processing and manufacturing sectors. Companies can't secure liability insurance or retail distribution agreements without federal clarity on permissible cannabinoid profiles.

State regulators have filled the void inconsistently. California's Department of Public Health maintains a list of 47 approved hemp cannabinoids, while Ohio permits only CBD and CBG in finished goods. The patchwork has effectively Balkanized the hemp market, with products legal in one state unmarketable in another.

Congressional Oversight Questions

The CRS report signals potential congressional scrutiny of FDA's hemp regulatory program, which has faced criticism for slow implementation since 2018. House Agriculture Committee staff requested the CRS analysis in July 2026 after industry complaints about the missing guidance reached a threshold that triggered formal inquiry.

The CRS documentation sets the stage for appropriations pressure. Congress can condition future FDA funding on meeting hemp guidance deadlines or redirect the rulemaking authority to USDA, which already oversees hemp cultivation under the Farm Bill.

FDA hasn't responded to CRS inquiries about a revised publication timeline, according to the report. The agency's hemp regulatory docket shows no active rulemaking entries for cannabinoid lists or container standards as of August 2026.

Container Guidance Gap Creates Safety Concerns

The missing container guidance was intended to establish child-resistant packaging standards and dosage labeling requirements for hemp products containing cannabinoids. Without federal standards, products reach consumers in packaging ranging from pharmaceutical-grade blister packs to unmarked dropper bottles with no dosage information.

Poison control centers reported a 340 percent increase in pediatric hemp product exposures between 2019 and 2025, according to data cited in the CRS report. That's a public health failure, the American Association of Poison Control Centers says.

FDA's existing dietary supplement regulations don't cover hemp cannabinoid products, creating a regulatory gap that the 2018 Farm Bill explicitly tasked the agency with closing. The container guidance was meant to adapt pharmaceutical packaging standards to hemp goods sold outside pharmacy channels.

What Happens Next

Industry observers expect the CRS report to trigger appropriations riders in the FY2027 Agriculture spending bill, which enters markup in September 2026. Congressional staff have floated language that would transfer hemp cannabinoid authority to USDA if FDA doesn't publish guidance by December 2026.

FDA's budget justification for FY2027, submitted in April, didn't mention hemp guidance as a priority. The agency requested $6.5 billion, with hemp regulation buried in a general "food safety modernization" line item that received no dedicated staffing increase.

For full background on this story, see the CannIntel topic hub on FDA Hemp Regulation.

The next signal will be whether FDA responds to the CRS report with a formal timeline before appropriations markup begins. Silence likely means USDA takes the wheel.